Johnson & Johnson (NYSE:JNJ) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now.
A smiling baby with an array of baby care products in the foreground.
Johnson & Johnson (NYSE:JNJ) has a sizable and broadly positioned operation, with strong representation in both the medical devices and pharmaceutical sectors. Its leading status in the industry is also supported by its robust efforts in research and development, as well as effective marketing capabilities.
In the second quarter of 2025, Johnson & Johnson (NYSE:JNJ) reported revenue of $23.7 billion, which showed a 5.77% growth from the same period last year. The company raised its full-year sales outlook by $2 billion to reflect a 5.4% increase, thanks to solid operational performance and positive foreign exchange impacts. It also boosted its earnings per share (EPS) forecast by $0.25, bringing it to $10.85. Meanwhile, adjusted operational EPS was revised to $10.68 at the midpoint.
In its earnings report, Johnson & Johnson (NYSE:JNJ) indicated that its portfolio and pipeline have set the stage for accelerated growth in the latter half of the year. It expects significant approvals and regulatory submissions in key areas such as lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular health— advancements that are likely to enhance and extend lives in meaningful ways.
Johnson & Johnson (NYSE:JNJ) is favored because of its strong dividend policy. The company has been growing its dividends for 63 consecutive years and currently pays a quarterly dividend of $1.30 per share. With a dividend yield of 3.09%, as of July 26, JNJ is among the best dogs of the Dow to invest in.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Top 10 Safest Dividend Stocks in the UK and Dividend Champions vs Aristocrats: 12 Under-the-Radar Stocks to Buy
Disclosure: None.